logo-loader
RNS
ReNeuron Group PLC

ReNeuron Group plc - Posting of Annual Report and Notice of AGM

RNS Number : 8010H
ReNeuron Group plc
02 August 2019
 

 

 

AIM: RENE


2 August 2019

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Posting of Annual Report and Accounts and Notice of AGM

 

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2019 and the Notice of the 2019 Annual General Meeting ("AGM") have been sent to shareholders and are also available on the Company's website at www.reneuron.com.

 

ReNeuron's AGM will be held at 10.00am on Thursday 12 September 2019 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

 

ENDS

 

Enquiries:

 

ReNeuron

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham




Stifel Nicolaus Europe Limited

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

N+1 Singer

Aubrey Powell, James Moat, Iqra Amin (Joint Broker)

 

+44 (0) 20 7496 3000

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSUUVSRKBAWRAR
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read